Even though dietary research projects are expensive to conduct, two physician researchers are pooling all of their resources to study the health benefits of following the Paleolithic or hunter-gatherer diet enjoyed by our ancestors.
Thanks to UCSF immunologists including Jeff Bluestone, PhD and Todd Brusko, PhD, a paradigm shift in thinking has occurred regarding the immune system’s role in type 1 diabetes. Previously, the goal was to suppress the immune system so insulin-producing beta cells weren’t destroyed.
Once again, the National Institute of Diabetes, Digestive & Kidney Diseases (NIDDK) has designated the UCSF Diabetes Center as a Diabetes Endocrinology Research Center (DERC), one of only 10 programs nationally to hold this prestigious rank.
What better way to describe the clinical trial experience than through the eyes of a study participant? In this month's Popular Science magazine, journalist Catherine Price writes about her experience in a new-onset type 1 diabetes clinical study involving the monoclonal antibody anti-CD3.
Since March is National Kidney Month and March 11, 2010 is officially World Kidney Day, we'd like to acknowledge the tremendous success of our UCSF Transplantation Program. UCSF has performed more kidney transplants than any other institution in the world — more than 8,300 since 1964 — and is the fifth largest center for living-donor kidney transplants in the country.
Bay area employers are concerned about the rising incidence of diabetes in today's society. One of three families are affected by diabetes or at risk for contracting this disease. Providing education on diabetes prevention, warning signs, common myths, and general treatment options is vitally important to keep staff healthy and happy.
At the 7th World Congress on Insulin Resistance, researchers from the UCSF Diabetes Center received awards for their new research involving insulin resistance. Sinan Tanyolac, MD, a UCSF visiting scholar from Istanbul University who works closely with Diabetes Center researchers Ira Goldfine, MD and John Kane, MD , received first place for studies on the genetics of insulin resistance and type 2 diabetes.
It is hard to believe that a single patient can lead to new insights into autoimmune disease that merit publication in the New England Journal of Medicine (NEJM) . In a recent Letter to the Editor in the journal, our DC investigators report the case of a patient seen at the San Francisco General Hospital with symptoms of autoimmune polyglandular syndrome type 1 (APS1).
A recent study involving a previously unstudied gene known as Rfx6 has shown how this gene is necessary for cells to differentiate into insulin-producing beta cells and other cells in the pancreas. This study was led by Michael German, MD, Diabetes Center Clinical Director and the Justine K. Schreyer Endowed Chair in Diabetes Research, and his colleague Constantin Polychronakos, MD, of McGill University.
Forbes magazine’s annual feature on the Most Powerful People included UCSF Chancellor Susan Desmond-Hellmann, MD, MPH, among the world’s seven Most Powerful Innovators. The story appearing in the November 30 issue called Desmond-Hellmann a “hero to legions of cancer patients” for her role in the development of the cancer drugs Avastin and Herceptin.
In conjunction with last month's National Diabetes Month, KPIX CBS 5 in San Francisco spotlighted the work of the Diabetes Center at UCSF. On November 10th, CBS 5 Healthwatch Doctor Kim Mulvihill, MD discussed an experimental drug called anti-CD3 and how it may stop beta cell destruction in type 1 diabetes.
Three Diabetes Center affiliated researchers are featured in a recent issue of Forefront magazine, a publication of the American Diabetes Association (ADA). Robert Farese Jr., MD, a senior scientist at the UCSF Gladstone Institute of Cardiovascular Disease, is studying the biology of fat storage.
Within the last year, one of our type 1 diabetes clinical trials involving an effective cancer drug concluded. Results published in November 2009 in the New England Journal of Medicine (NEJM)shows that anti-CD20 (FDA approved and marketed as Rituxan) has been shown to be effective in new onset diabetes by slowing down the progression of the disease.